Related Experiment Videos
How I treat central venous access device-related upper extremity deep vein thrombosis
Anita Rajasekhar1, Michael B Streiff2,3
1Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL; and.
Insights
Central venous access device (CVAD)-related thrombosis (CRT) is a common complication. Minimizing risk factors is key, as pharmacologic prevention benefits are unproven, and diagnosis relies on venous duplex.
Area of Science:
- Vascular Medicine
- Hematology
- Medical Devices
Background:
- Central venous access devices (CVADs) are essential for medical care but pose risks.
- Central venous access device-related thrombosis (CRT) is a frequent complication with serious consequences.
Observation:
- Risk factors for CRT include patient, device, and treatment-related elements.
- Pharmacologic thromboprophylaxis for CRT prevention lacks established clinical benefit despite numerous trials.
Findings:
- Venous duplex ultrasound is the recommended diagnostic tool for CRT.
- Treatment for CRT involves anticoagulation for at least 3 months or CVAD duration.
- Thrombolysis and CVAD removal are considered in specific clinical scenarios.
Implications:
- Minimizing patient exposure to known risk factors is the primary preventive strategy for CRT.
- Optimal management strategies for CRT require further investigation through prospective studies.
- Avoiding superior vena cava filters is recommended in CRT management.
Abstract:
Central venous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring central venous access as part of their medical care. Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous access, and postthrombotic syndrome. Patient-, device-, and treatment-related factors can influence the risk of CRT. Despite numerous randomized controlled trials, the clinical benefit of pharmacologic thromboprophylaxis for the prevention of CRT remains to be established. Therefore, minimizing patient exposure to known risk factors is the best available approach to prevent CRT. Venous duplex is recommended for the diagnosis of CRT. Anticoagulation for at least 3 months or the duration of the indwelling CVAD is recommended for treatment of CRT. Thrombolysis should be considered for patients at low risk for bleeding who have limb-threatening thrombosis or whose symptoms fail to resolve with adequate anticoagulation. CVAD removal should be consider for patients with bacteremia, persistent symptoms despite anticoagulation, and if the CVAD is no longer needed. Superior vena cava filters should be avoided. Prospective studies are needed to define the optimal management of patients with or at risk for CRT.